APA (7th ed.) Citation

Zhou C, Wei J, Xu K, Lin Y, Zhang L, & Li X. (2023). Cost-Effectiveness Analysis of Tislelizumab Plus Chemotherapy as First-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma in China. Dove Medical Press.

Chicago Style (17th ed.) Citation

Zhou C, Wei J, Xu K, Lin Y, Zhang L, and Li X. Cost-Effectiveness Analysis of Tislelizumab Plus Chemotherapy as First-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma in China. Dove Medical Press, 2023.

MLA (9th ed.) Citation

Zhou C, et al. Cost-Effectiveness Analysis of Tislelizumab Plus Chemotherapy as First-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma in China. Dove Medical Press, 2023.